

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Marbotis 3mg/ml + 10mg/ml + 1mg/ml ear drops, suspension for dogs

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml contains:

#### **Active substances:**

Marbofloxacin.....3.0 mg  
Clotrimazole..... 10.0 mg  
Dexamethasone acetate..... 1.0 mg  
(equivalent to Dexamethasone .....0.9 mg)

#### **Excipients:**

<b>Qualitative composition of excipients and other constituents</b>	<b>Quantitative composition if that information is essential for proper administration of the veterinary medicinal product</b>
Propyl gallate (E310)	1.0 mg
Sorbitan oleate	
Silica, colloidal hydrophobic	
Triglycerides, medium-chain	

Homogenous beige to yellow oily suspension.

### **3. CLINICAL INFORMATION**

#### **3.1 Target species**

Dogs

#### **3.2 Indications for use for each target species**

Treatment of otitis externa of bacterial and fungal origin – respectively due to bacteria sensitive to marbofloxacin, and fungi (*Malassezia pachydermatis* sensitive to clotrimazole).

#### **3.3 Contraindications**

Do not administer to dogs suffering from perforation of the tympanic membrane. Do not use in cases of hypersensitivity to the active substance, or to any of the excipients.

Do not administer to pregnant or lactating bitches.

### 3.4 Special warnings

None.

### 3.5 Special precautions for use

#### Special precautions for safe use in the target species:

Use of the product should be based on identification and susceptibility testing of the target pathogen(s). If this is not possible, therapy should be based on epidemiological information and knowledge of susceptibility of the target pathogens at farm level, or at local/regional level. Use of the product should be in accordance with official, national and regional antimicrobial policies.

An antibiotic with a lower risk of antimicrobial resistance selection (lower AMEG category) should be used for first line treatment where susceptibility testing suggests the likely efficacy of this approach.

Before treating with the veterinary medicinal product, the integrity of the tympanic membrane must be verified.

The external ear canal should be meticulously cleaned and dried before treatment. Quinolone class drugs have been associated with cartilage erosions in weightbearing joints and other forms of arthropathy in immature animals of various species. The use of the veterinary medicinal product in young animals is not recommended.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to marbofloxacin, dexamethasone, clotrimazole should avoid contact with the veterinary medicinal product.

This veterinary medicinal product may cause skin and eye irritation. Avoid contact with skin and eyes. In case of accidental contact, wash exposed area thoroughly with water.

Wash hands after use.

In case of accidental ingestion or if skin and eye symptoms persist seek medical advice immediately and show the package leaflet or the label to the physician.

#### Special precautions for the protection of the environment:

Not applicable.

### 3.6 Adverse events

Dogs:

Undetermined frequency (cannot be estimated from the available data)	Elevated serum alkaline phosphatase (ALP) and aminotransferase* Neutrophilia (limited)* Adrenal gland disorder (suppression of function)** Skin thinning** Delayed healing (wounds)**
Rare	Deafness***

(1 to 10 animals / 10,000 animals treated):	
---	--

\* Usual adverse reactions associated with corticosteroid drugs such as changes in biochemical and haematological parameters may be observed.

\*\* Prolonged and intensive use of topical corticosteroid preparations is known to trigger local and systemic effects

\*\*\*Mainly in elderly dogs and mostly of a transient nature

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder <or its local representative> or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### **3.7 Use during pregnancy, lactation or lay**

Pregnancy and lactation:

Do not use during pregnancy and lactation.

### **3.8 Interaction with other medicinal products and other forms of interaction**

None known.

### **3.9 Administration routes and dosage**

Auricular use.

Shake well before use and squeeze gently to fill the dropper with the veterinary medicinal product.

Apply ten drops into the ear once daily for 7 to 14 days.

After 7 days of treatment, the veterinary surgeon should evaluate the necessity to extend the treatment another week.

One drop of the preparation contains 71µg marbofloxacin, 237µg clotrimazole and 23.7µg dexamethasone acetate.

After application, the base of the ear may be massaged briefly and gently to allow the preparation to penetrate to the lower part of the ear canal.

The external ear canal should be meticulously cleaned and dried before treatment.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

Changes in biochemical and hæmatological parameters (such as increase of alkaline phosphatase, aminotransferase, some limited neutrophilia, eosinopenia, lymphopenia) are observed with three fold the recommended dosage; such changes are not serious and will reverse once the treatment has stopped.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### 3.12 Withdrawal periods

Not applicable.

## 4. PHARMACOLOGICAL INFORMATION

### 4.1 ATCvet code: QS02CA06

### 4.2 Pharmacodynamics

The preparation combines three active ingredients:

- marbofloxacin, a synthetic bactericidal agent belonging to the fluoroquinolone family that acts by inhibiting DNA gyrase. It exhibits a broad spectrum of activity against Gram-positive bacteria (e.g. *Staphylococcus intermedius*) and against Gram-negative organisms (*Pseudomonas aeruginosa*, *Escherichia coli* and *Proteus mirabilis*).
- clotrimazole, an anti-fungal agent that belongs to the imidazole family and which acts by causing changes in membrane permeability, allowing intracellular compounds to leak from the cell and thus inhibiting cellular molecular synthesis. It exhibits a wide spectrum of activity and is aimed, in particular, at *Malassezia pachydermatis*;
- dexamethasone acetate, a synthetic glucocorticoid exhibiting anti-inflammatory and anti-pruritic activity.

### 4.3 Pharmacokinetics

Pharmacokinetics studies in dogs at the therapeutic dosage have shown that: Marbofloxacin plasma concentrations peak at 0.06 µg/ml on the 14th day of treatment.

Marbofloxacin binds weakly to plasma proteins (< 10% in dogs) and is eliminated slowly, mainly in the active form, over 2/3 in urine and over 1/3 in faeces. Clotrimazole absorption is extremely poor (plasma concentration < 0.04 µg/ml).

Dexamethasone acetate plasma concentration reaches 1.25 ng/ml on the 14<sup>th</sup> day of treatment. Dexamethasone resorption is not increased by the inflammatory process induced by otitis.

## 5. PHARMACEUTICAL PARTICULARS

### 5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

### 5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years

Shelf life after first opening the immediate packaging: 6 months

### 5.3 Special precautions for storage

Do not store above 30°C.

#### **5.4 Nature and composition of immediate packaging**

A white LDPE bottle with white LDPE applicator (dropper), closed with white HDPE tamper evident cap.

Package sizes:

Cardboard box with 1 bottle of 15 ml.

Cardboard box with 1 bottle of 25 ml.

Not all pack sizes may be marketed.

#### **5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

### **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Vet-Agro Multi-Trade Company Sp. z o. o.

### **7. MARKETING AUTHORISATION NUMBER**

Vm 55788/3000

### **8. DATE OF FIRST AUTHORISATION**

20 September 2024

### **9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

20 September 2024

### **10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

For UK(NI) only: Find more product information by searching for the 'Product Information Database' or 'PID' on [www.gov.uk](http://www.gov.uk).

*Gavin Hall*

Approved: 20 September 2024